A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases
| Autor: | Yasmina Juarranz, Selene Pérez-García, Mar Carrión, Rosa P. Gomariz, Mario Mellado, A. Lamana, Isidoro González-Álvaro, Raúl Villanueva-Romero, David Martín Castro, Irene Gutiérrez-Cañas, Carmen Martínez |
|---|---|
| Přispěvatelé: | European Commission, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III |
| Rok vydání: | 2019 |
| Předmět: |
Receptors
Vasoactive Intestinal Polypeptide Type I type 1 diabetes Vasoactive intestinal peptide Endogeny Review Inflammatory bowel disease Catalysis Autoimmune Diseases Inorganic Chemistry Immune system inflammatory bowel disease VPAC1 receptor Animals Humans Endocrine system Medicine Physical and Theoretical Chemistry Receptor Molecular Biology Spectroscopy vasoactive intestinal peptide Inflammation Biología celular business.industry Organic Chemistry biomarkers General Medicine Inflammatory Bowel Diseases medicine.disease Precision medicine Computer Science Applications Diabetes Mellitus Type 1 Sjogren's Syndrome Sjögren’s syndrome Immunology rheumatic diseases central nervous system diseases Receptors Vasoactive Intestinal Peptide Type II business Homeostasis VPAC2 receptor |
| Zdroj: | E-Prints Complutense: Archivo Institucional de la UCM Universidad Complutense de Madrid Digital.CSIC. Repositorio Institucional del CSIC instname E-Prints Complutense. Archivo Institucional de la UCM International Journal of Molecular Sciences |
| ISSN: | 2015-3562 |
| Popis: | The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP’s discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases. This work was supported by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (Grants N°: PI14/ 00477, PI17/00027, RD16/0012/0008, RD16/0012/0011) and by the Ministerio de Economía y Competitividad (RTC-2015-3562-1), co-financed by Fondo Europeo de Desarrollo Regional (FEDER). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|